The anti-tumor activity of shikonin related to the inhibition of PKM2 has also been shown in studies involving such tumors as cholangiocarcinoma, Lewis lung carcinoma, melanoma, esophageal cancer, and hepatocellular carcinoma [111,112,113]. This evidence concerns the gene PKM and hepatocellular carcinoma.